<p>Xeris Biopharma（纳斯达克：XERS - 获取免费报告）预计将在 2025 年 8 月 7 日星期四市场开盘前发布其 2025 年第二季度财报。分析师预计 Xeris Biopharma 本季度每股收益为（$0.03），收入为 6458 万美元。Xeris Biopharma 已将其 2025 财年的指引设定为每股收益。</p>
<p>Xeris Biopharma（纳斯达克：XERS - 获取免费报告）最近一次发布季度财报是在 5 月 8 日星期四。该公司报告本季度每股收益为（$0.06），超出分析师共识预期的（$0.07）$0.01。该公司本季度的收入为 5780 万美元，而分析师预期为 5761 万美元。分析师平均预计 Xeris Biopharma 在当前财年和下一个财年的每股收益均为$0。</p>
<p>获取 <strong>Xeris Biopharma</strong> 警报：</p>
<h2>Xeris Biopharma 股价上涨 1.7%</h2>
<p>在周五的交易中，纳斯达克 XERS 的股票上涨了$0.09，达到了$5.18。该公司交易了 616,563 股，较其平均交易量 2406861 股有所减少。该公司的 50 日简单移动平均为$4.83，200 日简单移动平均为$4.46。该股票的市值为 8.0927 亿美元，市盈率为-17.15，贝塔值为 0.66。Xeris Biopharma 的 12 个月低点为$2.10，12 个月高点为$6.07。</p>
<h2>Xeris Biopharma 内部交易</h2>
<p>在其他新闻中，内部人士 Kevin Mcculloch 在 6 月 13 日星期五购买了 25,000 股该公司的股票。每股平均购买价格为$4.38，总价值为$109,500.00。交易完成后，该内部人士直接持有该公司 1,708,585 股股票，价值$7,483,602.30。这笔交易代表了他们持股比例的 1.48% 的增加。该交易已在证券交易委员会的备案中披露，相关文件可在此链接查看。目前，内部人士持有该股票的 6.47%。</p>
<h2>Xeris Biopharma 的机构交易</h2>
<p>一些机构投资者和对冲基金最近增加或减少了对该公司的持股。Acadian Asset Management LLC 在第一季度购买了 Xeris Biopharma 的新股份，价值$96,000。Caxton Associates LLP 在第一季度购买了 Xeris Biopharma 的新股份，价值$170,000。高盛集团在第一季度将其在 Xeris Biopharma 的持股增加了 75.4%。高盛集团目前持有该公司 2,790,014 股股票，价值$15,317,000，此前在该期间内又收购了 1,199,435 股。Millennium Management LLC 在第一季度将其在 Xeris Biopharma 的持股增加了 19.0%。Millennium Management LLC 目前持有该公司 2,317,972 股股票，价值$12,726,000，此前在该期间内又收购了 369,420 股。最后，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Xeris Biopharma 的持股增加了 4.5%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前持有该公司 83,982 股股票，价值$461,000，此前在该期间内又收购了 3,594 股。对冲基金和其他机构投资者持有该公司 42.75% 的股份。</p>
<h2>分析师评级上调和下调</h2>
<p>几位股票分析师最近对 XERS 股票发表了看法。华尔街 Zen 在 5 月 22 日星期四的研究报告中将 Xeris Biopharma 的评级从 “买入” 下调至 “持有”。Oppenheimer 在 5 月 9 日星期五的研究报告中将 Xeris Biopharma 的目标价从$6.00 上调至$7.00，并给予该股票 “跑赢大盘” 的评级。两位分析师对该股票给予了持有评级，五位分析师对该公司的股票给予了买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为$6.25。</p>
<p><strong>阅读我们关于 Xeris Biopharma 的最新报告</strong></p>
<h2>关于 Xeris Biopharma</h2>
<p>（获取免费报告）</p>
<p>Xeris Biopharma Holdings, Inc 是一家生物制药公司，专注于在伊利诺伊州开发和商业化疗法。该公司提供 Gvoke，一种用于治疗严重低血糖的即用型液体稳定胰高血糖素，适用于儿童和成人患者；Keveyis，一种用于治疗高钾血症、低钾血症及相关类型的原发性周期性麻痹的疗法；以及 Recorlev，一种用于治疗库欣综合症成人患者内源性高皮质醇血症的皮质醇合成抑制剂。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Xeris Biopharma</li>
<li>现在购买的三只最佳蓝筹股</li>
<li>Rocket Lab 下周报告：投资者需要知道的事项</li>
<li>低市盈率成长股：开启投资机会</li>
<li>苹果股票：大盈利，小波动——是时候买入了吗？</li>
<li>如何开始投资房地产</li>
<li>亚马逊的盈利：接下来会发生什么以及如何应对</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVSUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVSUw"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Xeris Biopharma 吗？</h2>
<p>在你考虑 Xeris Biopharma 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前买入……而 Xeris Biopharma 并不在其中。</p>
<p>虽然 Xeris Biopharma 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

XERS

<p>Xeris Biopharma (NASDAQ:XERS) 将于 2025 年 8 月 7 日星期四市场开盘前发布其 2025 年第二季度财报。（查看财报请访问 https://www.marketbeat.）</p>

<p>Xeris Biopharma (NASDAQ:XERS - Get Free Report) is anticipated to release its Q2 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect Xeris Biopharma to post earnings of ($0.03) per share and revenue of $64.58 million for the quarter. Xeris Biopharma has set its FY 2025 guidance at EPS.</p>
<div class="lb-trans"><p>Xeris Biopharma（纳斯达克：XERS - 获取免费报告）预计将在 2025 年 8 月 7 日星期四市场开盘前发布其 2025 年第二季度财报。分析师预计 Xeris Biopharma 本季度每股收益为（$0.03），收入为 6458 万美元。Xeris Biopharma 已将其 2025 财年的指引设定为每股收益。</p>
</div><p>Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The firm had revenue of $57.80 million for the quarter, compared to analyst estimates of $57.61 million. On average, analysts expect Xeris Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Xeris Biopharma（纳斯达克：XERS - 获取免费报告）最近一次发布季度财报是在 5 月 8 日星期四。该公司报告本季度每股收益为（$0.06），超出分析师共识预期的（$0.07）$0.01。该公司本季度的收入为 5780 万美元，而分析师预期为 5761 万美元。分析师平均预计 Xeris Biopharma 在当前财年和下一个财年的每股收益均为$0。</p>
</div><p>Get <strong>Xeris Biopharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Xeris Biopharma</strong> 警报：</p>
</div><h2>Xeris Biopharma Trading Up 1.7%</h2>
<div class="lb-trans"><h2>Xeris Biopharma 股价上涨 1.7%</h2>
</div><p>Shares of NASDAQ XERS traded up $0.09 during trading on Friday, reaching $5.18. 616,563 shares of the company traded hands, compared to its average volume of 2,406,861. The firm's fifty day simple moving average is $4.83 and its 200 day simple moving average is $4.46. The stock has a market cap of $809.27 million, a P/E ratio of -17.15 and a beta of 0.66. Xeris Biopharma has a 12-month low of $2.10 and a 12-month high of $6.07.</p>
<div class="lb-trans"><p>在周五的交易中，纳斯达克 XERS 的股票上涨了$0.09，达到了$5.18。该公司交易了 616,563 股，较其平均交易量 2406861 股有所减少。该公司的 50 日简单移动平均为$4.83，200 日简单移动平均为$4.46。该股票的市值为 8.0927 亿美元，市盈率为-17.15，贝塔值为 0.66。Xeris Biopharma 的 12 个月低点为$2.10，12 个月高点为$6.07。</p>
</div><h2>Insider Transactions at Xeris Biopharma</h2>
<div class="lb-trans"><h2>Xeris Biopharma 内部交易</h2>
</div><p>In other news, insider Kevin Mcculloch bought 25,000 shares of the business's stock in a transaction on Friday, June 13th. The shares were bought at an average price of $4.38 per share, with a total value of $109,500.00. Following the completion of the transaction, the insider directly owned 1,708,585 shares in the company, valued at $7,483,602.30. This trade represents a 1.48% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. 6.47% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士 Kevin Mcculloch 在 6 月 13 日星期五购买了 25,000 股该公司的股票。每股平均购买价格为$4.38，总价值为$109,500.00。交易完成后，该内部人士直接持有该公司 1,708,585 股股票，价值$7,483,602.30。这笔交易代表了他们持股比例的 1.48% 的增加。该交易已在证券交易委员会的备案中披露，相关文件可在此链接查看。目前，内部人士持有该股票的 6.47%。</p>
</div><h2>Institutional Trading of Xeris Biopharma</h2>
<div class="lb-trans"><h2>Xeris Biopharma 的机构交易</h2>
</div><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Acadian Asset Management LLC purchased a new stake in shares of Xeris Biopharma during the first quarter worth $96,000. Caxton Associates LLP purchased a new stake in shares of Xeris Biopharma during the first quarter worth $170,000. Goldman Sachs Group Inc. increased its position in shares of Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company's stock worth $15,317,000 after acquiring an additional 1,199,435 shares during the period. Millennium Management LLC increased its position in shares of Xeris Biopharma by 19.0% during the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company's stock worth $12,726,000 after acquiring an additional 369,420 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Xeris Biopharma by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company's stock worth $461,000 after acquiring an additional 3,594 shares during the period. Hedge funds and other institutional investors own 42.75% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近增加或减少了对该公司的持股。Acadian Asset Management LLC 在第一季度购买了 Xeris Biopharma 的新股份，价值$96,000。Caxton Associates LLP 在第一季度购买了 Xeris Biopharma 的新股份，价值$170,000。高盛集团在第一季度将其在 Xeris Biopharma 的持股增加了 75.4%。高盛集团目前持有该公司 2,790,014 股股票，价值$15,317,000，此前在该期间内又收购了 1,199,435 股。Millennium Management LLC 在第一季度将其在 Xeris Biopharma 的持股增加了 19.0%。Millennium Management LLC 目前持有该公司 2,317,972 股股票，价值$12,726,000，此前在该期间内又收购了 369,420 股。最后，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Xeris Biopharma 的持股增加了 4.5%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前持有该公司 83,982 股股票，价值$461,000，此前在该期间内又收购了 3,594 股。对冲基金和其他机构投资者持有该公司 42.75% 的股份。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调和下调</h2>
</div><p>Several equities analysts recently weighed in on XERS shares. Wall Street Zen lowered Xeris Biopharma from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Thursday, May 22nd. Oppenheimer boosted their price objective on Xeris Biopharma from $6.00 to $7.00 and gave the stock an &#34;outperform&#34; rating in a research note on Friday, May 9th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $6.25.</p>
<div class="lb-trans"><p>几位股票分析师最近对 XERS 股票发表了看法。华尔街 Zen 在 5 月 22 日星期四的研究报告中将 Xeris Biopharma 的评级从 “买入” 下调至 “持有”。Oppenheimer 在 5 月 9 日星期五的研究报告中将 Xeris Biopharma 的目标价从$6.00 上调至$7.00，并给予该股票 “跑赢大盘” 的评级。两位分析师对该股票给予了持有评级，五位分析师对该公司的股票给予了买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为$6.25。</p>
</div><p><strong>Read Our Latest Report on Xeris Biopharma</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Xeris Biopharma 的最新报告</strong></p>
</div><h2>About Xeris Biopharma</h2>
<div class="lb-trans"><h2>关于 Xeris Biopharma</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.</p>
<div class="lb-trans"><p>Xeris Biopharma Holdings, Inc 是一家生物制药公司，专注于在伊利诺伊州开发和商业化疗法。该公司提供 Gvoke，一种用于治疗严重低血糖的即用型液体稳定胰高血糖素，适用于儿童和成人患者；Keveyis，一种用于治疗高钾血症、低钾血症及相关类型的原发性周期性麻痹的疗法；以及 Recorlev，一种用于治疗库欣综合症成人患者内源性高皮质醇血症的皮质醇合成抑制剂。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Xeris Biopharma</li>
<li>The 3 Best Blue-Chip Stocks to Buy Now</li>
<li>Rocket Lab Reports Next Week: Here’s What Investors Should Know</li>
<li>Low PE Growth Stocks: Unlocking Investment Opportunities</li>
<li>Apple Stock: Big Earnings, Small Move—Time to Buy?</li>
<li>How to Start Investing in Real Estate</li>
<li>Amazon's Earnings: What Comes Next and How to Play It</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Xeris Biopharma</li>
<li>现在购买的三只最佳蓝筹股</li>
<li>Rocket Lab 下周报告：投资者需要知道的事项</li>
<li>低市盈率成长股：开启投资机会</li>
<li>苹果股票：大盈利，小波动——是时候买入了吗？</li>
<li>如何开始投资房地产</li>
<li>亚马逊的盈利：接下来会发生什么以及如何应对</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVSUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=XERS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Xeris Biopharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Xeris Biopharma 吗？</h2>
</div><p>Before you consider Xeris Biopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Xeris Biopharma 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前买入……而 Xeris Biopharma 并不在其中。</p>
</div><p>While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Xeris Biopharma 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Xeris Biopharma (XERS) 预计将在周四宣布财报